Literature DB >> 17674979

How much radiation is the chemotherapy worth in advanced head and neck cancer?

Mohit Kasibhatla1, John P Kirkpatrick, David M Brizel.   

Abstract

PURPOSE: To estimate the radiotherapeutic dose equivalence of chemoradiotherapy in head and neck cancer.
METHODS: The biologic equivalent dose (BED) of radiotherapy in nine trials of standard and five trials of modified fractionated radiotherapy with or without chemotherapy was calculated using the linear-quadratic formulation. Data from Radiation Therapy Oncology Group (RTOG) study 90-03 were used to calculate the relationship (S) between increase in locoregional control (LRC) and increase in BED with modified vs. standard fractionated radiotherapy. The increase in LRC with chemoradiotherapy vs. radiotherapy alone, the BED of the radiotherapy-alone arms, and the "S" value were used to calculate the BED contribution from chemotherapy and the total BED of chemoradiotherapy from each study.
RESULTS: From RTOG 90-03, a 1% increase in BED yields a 1.1% increase in LRC. The mean BED of standard fractioned radiotherapy was 60.2 Gy(10) and 66 Gy(10) for modified fractionation. The mean BED of standard fractionated chemoradiotherapy was 71 Gy(10) (10.8 Gy(10) contributed by chemotherapy). The mean BED of modified fractionated chemoradiotherapy was 76 Gy(10) (10.4 Gy(10) contributed by chemotherapy).
CONCLUSIONS: Chemotherapy increases BED by approximately 10 Gy(10) in standard and modified fractionated radiotherapy, equivalent to a dose escalation of 12 Gy in 2 Gy daily or 1.2 Gy twice daily. Such an escalation could not be safely achieved by increasing radiation dose alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17674979     DOI: 10.1016/j.ijrobp.2007.03.025

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Models of acute mucosal tolerance to radiotherapy alone applied to synchronous chemoradiation schedules in head and neck cancer.

Authors:  Sara Meade; Paul Sanghera; John Glaholm; Andrew Hartley
Journal:  Tumour Biol       Date:  2013-10-09

2.  Can radiobiological parameters derived from squamous cell carcinoma of the head and neck be used to predict local control in anal cancer treated with chemoradiation?

Authors:  L Pettit; S Meade; P Sanghera; J Glaholm; J I Geh; A Hartley
Journal:  Br J Radiol       Date:  2013-01       Impact factor: 3.039

Review 3.  Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data.

Authors:  Nitin Ohri; Adam P Dicker; Yaacov Richard Lawrence
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-19       Impact factor: 7.038

Review 4.  Radio-chemotherapy for bladder cancer: Contribution of chemotherapy on local control.

Authors:  George A Plataniotis; Roger G Dale
Journal:  World J Radiol       Date:  2013-08-28

5.  Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.

Authors:  Patrick D Maguire; Charles R Neal; Stuart M Hardy; Andrew M Schreiber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-12-28       Impact factor: 7.038

Review 6.  Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature.

Authors:  José A González Ferreira; Javier Jaén Olasolo; Ignacio Azinovic; Branislav Jeremic
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-04

7.  Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.

Authors:  Mary Feng; Feng-Ming Kong; Milton Gross; Shaneli Fernando; James A Hayman; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-15       Impact factor: 7.038

Review 8.  Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?

Authors:  Stuart E Samuels; Avraham Eisbruch; Jonathan J Beitler; June Corry; Carol R Bradford; Nabil F Saba; Michiel W M van den Brekel; Robert Smee; Primož Strojan; Carlos Suárez; William M Mendenhall; Robert P Takes; Juan P Rodrigo; Missak Haigentz; Alexander D Rapidis; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-13       Impact factor: 3.236

9.  Dosimetric impact of target definitions on normal structures in head and neck cancer.

Authors:  Micah T Monaghan; James A Bonner; Philip E Schaner; Jimmy J Caudell
Journal:  Head Neck Oncol       Date:  2011-08-11

Review 10.  Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy.

Authors:  Ying-Chieh Yang; Chi-Shiun Chiang
Journal:  Front Oncol       Date:  2016-06-30       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.